Sun Pharma Secures Interim Win in Trademark Dispute

Sun Pharmaceutical Industries has secured interim relief from the Bombay High Court in a trademark dispute, strengthening its position in protecting branded pharmaceutical products.

The court restrained United Biotech from using any mark identical or deceptively similar to Sun Pharma’s “Octride.” The dispute centred on competing marks “Octride” and “Otide,” both used for drugs derived from Octreotide Acetate, prescribed for conditions such as acromegaly and carcinoid tumours.

In granting relief, the court found that Sun Pharma had the stronger claim, effectively safeguarding the company’s brand reputation and goodwill in the market.

From a commercial perspective, the ruling highlights the importance of trademark protection in pharmaceuticals, where similar naming can create confusion in high-stakes therapeutic areas. For large manufacturers, maintaining distinct branding remains critical not only for market share but also for regulatory and patient safety considerations.

The case will continue, but for now, Sun Pharma has secured a key legal advantage.